← 홈

ADC

1,048개 · ADC 1048 · Antibody 5323 · CGT 2737 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,048개
ADCSHOTFDACuratedFDABiologicDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 79.7%임상시험 224상태 APPROVED
ADCSFDAFDAHotBiologicSeagenvedotin and the anti-HER2 t…Approved

brentuximab vedotin (Adcetris)

Hodgkin Lymphoma · Hodgkin Disease

#HodgkinDisease#ADC#Approved#FDA승인#인기+5
효능 ORR 100%임상시험 175상태 ACTIVE
ADCSHOTFDACuratedFDABiologicRocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 80%임상시험 164상태 APPROVED
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 50%임상시험 152상태 ACTIVE
ADCSFDAFDABiologicRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA승인#인기+5
효능 ORR 100%임상시험 89상태 RECRUITING
ADCSFDAFDABiologicAstellasvedotin plus pembrolizumab …Approved

enfortumab vedotin (Padcev)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Renal Pelvis and Ureter Urothelial Carci

#RenalPelvisandUreterUrothelialCa#ADC#Approved#FDA승인#인기+5
효능 ORR 44%임상시험 84상태 RECRUITING
ADCAHOTFDACuratedFDABiologicGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 57%임상시험 76상태 DISCONTINUED
ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5
효능 ORR 79%임상시험 44상태 RECRUITING
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3
효능 ORR 33.3%임상시험 12상태 RECRUITING
ADCCFDAFDABiologicstaleAstellasPhase 3

enfortumab vedotin (Padcev, Enfortumab Vedotin-Ejfv)

Advanced or Metastatic Solid Malignancies · Advanced or Metastatic Solid Malignancie

#AdvancedorMetastaticSolidMaligna#ADC#Phase3#FDA승인#항체약물접합체+2
임상시험 1상태 ACTIVE
ADCCFDAFDABiologicstaleRochePreclinical

Polatuzumab Vedotin-Piiq (Polatuzumab Vedotin-Piiq)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Preclinical#FDA승인#항체약물접합체+2
임상시험 1상태 ACTIVE
ADCCFDAFDABiologicFDA approved (openFDA)Approved

DATOPOTAMAB DERUXTECAN-DLNK (DATOPOTAMAB DERUXTECAN-DLNK)

FDA-approved indication · See label

#Seelabel#ADC#Approved#FDA승인#항체약물접합체+3
임상시험 0상태 APPROVED
ADCCFDAFDABiologicFDA approved (openFDA)Approved

TELISOTUZUMAB VEDOTIN-TLLV (TELISOTUZUMAB VEDOTIN-TLLV)

FDA-approved indication · See label

#Seelabel#ADC#Approved#FDA승인#항체약물접합체+3
임상시험 0상태 APPROVED
ADCAHotBiologicImmunityBio, Inc.sPhase 3

Nab-paclitaxel (Nab-paclitaxel)

Triple Negative Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 69.1%임상시험 243상태 RECRUITING
ADCSHotBiologicJanssen Research & Development,…govitecan in a patient with…Approved

5-Fluorouracil (5-Fluorouracil)

Colorectal Neoplasms · Endometrial Cancer

#EndometrialCancer#ADC#Approved#인기#항체약물접합체+5
효능 ORR 72.7%임상시험 202상태 RECRUITING
ADCBHotBiologicAstraZenecavedotin plus PD-1 blockade …Phase 3

GEM (Gemcitabine, Gemcitabine (GEM))

Extranodal NK/T-cell Lymphoma · Nasopharyngeal Carcinoma (NPC)

#NasopharyngealCarcinomaNPC#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 50%임상시험 190상태 RECRUITING
ADCAHotBiologicBeOne Medicinesgovitecan in a patient with…Phase 3

5-FU (5-FU)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 85%임상시험 170상태 RECRUITING
ADCAHotBiologicCellerant TherapeuticsVedotin Therapy]Phase 3

Filgrastim (Filgrastim)

Male Breast Cancer; Stage II Breast Cancer · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88%임상시험 170상태 RECRUITING
ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 70.3%임상시험 164상태 RECRUITING

1 / 53 페이지

← 이전다음 →